Forbes Inc. v. Granada Biosciences, Inc.

124 S.W.3d 167, 32 Media L. Rep. (BNA) 1498, 47 Tex. Sup. Ct. J. 162, 2003 Tex. LEXIS 524, 2003 WL 22999362
CourtTexas Supreme Court
DecidedDecember 19, 2003
Docket01-0788
StatusPublished
Cited by522 cases

This text of 124 S.W.3d 167 (Forbes Inc. v. Granada Biosciences, Inc.) is published on Counsel Stack Legal Research, covering Texas Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Forbes Inc. v. Granada Biosciences, Inc., 124 S.W.3d 167, 32 Media L. Rep. (BNA) 1498, 47 Tex. Sup. Ct. J. 162, 2003 Tex. LEXIS 524, 2003 WL 22999362 (Tex. 2003).

Opinion

Justice O’NEILL

delivered the opinion of the Court,

in which Chief Justice PHILLIPS, Justice HECHT, Justice OWEN, Justice JEFFERSON, Justice SMITH, Justice WAINWRIGHT, and Justice BRISTER joined.

Granada Biosciences, Inc. and Granada Foods Corporation sued Forbes, Inc., publisher of Forbes magazine, and writer William P. Barrett for business disparagement. The trial court rendered summary judgment for Forbes and Barrett, and the court of appeals reversed. 49 S.W.3d 610. We hold that the court of appeals erred in reversing the trial court’s summary judgment because the plaintiffs produced no evidence that Forbes and Barrett acted with actual malice in publishing the article that is the subject of this controversy. Accordingly, we reverse the court of appeals’ judgment and render judgment for Forbes and Barrett.

I

In its issue dated November 11, 1991, Forbes published an article entitled “The Incredible Shrinking Empire.” 1 The article, authored by Barrett, focused on the financial condition of the Granada Corp., a privately held company, and on its chairman, David Eller. Granada Corp. was the parent of a number of other private and public entities. While the Granada organization consisted of dozens of entities, the article only named two of the public entities, Granada Foods Corp. (GFC) and Granada Biosciences, Inc. (GBI). In general, the Granada entities were engaged in developing and applying advanced technology in the area of agriculture, primarily cattle production. The article noted that the Wall Street Journal had described Granada Corp. as a “corporate start ] of the future” in 1989, and that the organization, under Eller’s stewardship, had garnered much favorable publicity. But, the article said, “there is less to Granada than meets the eye. Actually, its total revenues, $1 billion as recently as 1988, will scarcely be $200 million for 1991. Profits: zilch. Granada’s work force has shrunk to below 900 from 2,200; its cattle herd has dwindled to 25,000 from 1 million.” The article identified GFC and GBI as the two publicly traded stock companies within the Granada organization, and said that they were “so broke they haven’t been able to publish their 1990 annual reports.” It went on to say that “Granada is beset with a series of serious shareholder lawsuits,” including one filed by “Fort Worth near-billionaire Edward Bass.” It is undisputed that, while a person with that name had sued one of the Granada entities, it was not the “Fort Worth near-billionaire.” Furthermore, the article described a number of other signs of serious financial trouble: “Possibly anticipating a bankruptcy filing, former Granada employees say officials in recent months have moved some farm equipment and vehicles off Granada books and gotten rid of backup documentation.”

According to Barrett’s affidavit, he used the term “Granada” in a generic sense to describe the various entities controlled by Eller, and when he “intended to specifically address Granada Biosciences, Inc. or Granada Food Corporation, [he] did so by *170 name.” The day the article was released, the shares of GBI and GFC dropped precipitously, and trading was permanently suspended in early 1992.

GBI, GFC, Eller, and his wife, Linda, sued Barrett, Forbes, Inc., and Cheryl Munke, an employee of a former Granada affiliate, for damages allegedly caused by the article’s publication. Forbes and Barrett (collectively “Forbes”) filed joint motions for summary judgment, which the trial court granted. On appeal, the Seventh District court of appeals, to which the case was transferred, reversed, holding that Forbes’s summary judgment motion did not address the plaintiffs’ business disparagement claims. Granada Biosciences, Inc. v. Barrett, 958 S.W.2d 215, 221 (Tex.App.-Amarillo 1997, pet. denied). 2 On remand, Forbes filed a renewed and supplemental summary judgment motion under Rule 166a(e) and(i), which specifically addressed the plaintiffs’ business disparagement claims. The trial court again granted summary judgment in Forbes’s favor, but the Fourteenth District court of appeals reversed, concluding that several fact issues precluded summary judgment. The court determined that there were fact issues concerning whether the article as a whole and several specific passages in the article were false and disparaging. 49 S.W.3d at 621-22. The court agreed with Forbes’s contention that, to recover on their business disparagement claims, the plaintiffs were required to satisfy the constitutional actual-malice standard the United States Supreme Court established in New York Times v. Sullivan, 376 U.S. 254, 84 S.Ct. 710, 11 L.Ed.2d 686 (1964), but held that a fact issue on Forbes’s state of mind at the time of publication precluded summary judgment. We hold that GBI and GFC presented no evidence of actual malice under the New York Times standard, and thus reverse the court of appeals’ judgment.

II

To prevail on a business disparagement claim, a plaintiff must establish that (1) the defendant published false and disparaging information about it, (2) with malice, (3) without privilege, (4) that resulted in special damages to the plaintiff. Hurlbut v. Gulf Atl. Life Ins. Co., 749 S.W.2d 762, 766 (Tex.1987). A business disparagement claim is similar in many respects to a defamation action. Id. The two torts differ in that defamation actions chiefly serve to protect the personal reputation of an injured party, while a business disparagement claim protects economic interests. Id. In Hurlbut, a suit brought by an insurance agent against his former employer, we noted that a business disparagement defendant may be held liable “only if he knew of the falsity or acted with reckless disregard concerning it, or if he acted with ill will or intended to interfere in the economic interest of the plaintiff in an unprivileged fashion.” Id. (emphasis added) (quoting Restatement (Seoond) of ToRts § 623A, cmt. g (1977)).

The court of appeals noted in this case that GBI and GFC did not dispute Forbes’s contention that they were “public figures for the purpose of discussing their respective financial statuses,” a conclusion that GBI and GFC do not challenge here. 49 S.W.3d at 615 n. 2. The court then held that ill will or intent to interfere with the plaintiffs economic interest will not suffice to establish malice in a business disparagement claim brought by a public figure *171 against a media defendant. Id. at 618. Instead, the court held that the constitutional interests at stake — “the conflict between constitutionally-protected free expression and a state’s power to award damages based on a defendant’s statements” — require proof of actual malice under the standard the United States Supreme Court articulated in New York Times. Id. at 618.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Robert Rodriguez v. Scott Ginsburg
Court of Appeals of Texas, 2019
Claude E. Welch v. Jeremy Crew
Court of Appeals of Texas, 2018

Cite This Page — Counsel Stack

Bluebook (online)
124 S.W.3d 167, 32 Media L. Rep. (BNA) 1498, 47 Tex. Sup. Ct. J. 162, 2003 Tex. LEXIS 524, 2003 WL 22999362, Counsel Stack Legal Research, https://law.counselstack.com/opinion/forbes-inc-v-granada-biosciences-inc-tex-2003.